Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Israeli company MeMed has developed a proprietary diagnostic platform which uses proprietary immune system biomarkers to rapidly distinguish between viral and bacterial infections. The firm already has a CE -marked lab-based product, ImmunoXpert, which has been validated in three studies, the last of that trilogy having just published results confirming the test's ability to accurately distinguish between bacterial and viral infections.
With its coffers topped up and a new CEO in place, Lumicell is forging ahead with clinical trials of its LUM real-time, cancer imaging system, designed to improve the outcomes of surgical resection of tumors. The company's first target indication is for breast cancer and it is aiming for a US premarket approval in late Q1 of 2019.
Having secured Medicare reimbursement, Seattle, Washington-based Indi Diagnostics, Inc. is getting ready to bring its liquid biopsy molecular test to pulmonologists in the US starting Q1 2018. The company said it will be first to introduce a liquid biopsy molecular diagnostic test in the country designed to help pulmonologists identify lung nodules that have a high probability of being benign, saving patients unnecessary invasive procedures.
Start-Up Spotlight: Arkis BioSciences, Endexo-Boosted Ventricular Drainage Catheter Reduces Obstructions
Arkis BioSciences Inc.'s newly launched CerebroFlo EVD catheter for treating intracranial hypertension offers an added benefit of being impregnated with Endexo, an antiocclusive agent that in laboratory studies has shown to dramatically reduce the incidence of thrombus formation, which can potentially reduce catheter obstructions.
Israeli start-up Augmedics is developing an augmented reality vision system designed to give surgeons "X-ray vision." The company's ViZOR system uses see-through AR optics to project a 3D image of a patient's spine onto a surgeon's retina, in real-time.
Peritoneal dialysis (PD) can allow renal patients to dialyze at home, but connecting one’s catheter to the equipment carries an infection risk and is too tricky for some patients. Swiss startup Peripal AG, which closed a Series A1 round with prominent Swiss investors in July, is betting that its patient-aid device will make PD easier and safer while cutting costs for medical systems.
Results of the VITAL trial show Cerebrotech's non-invasive portable VIPS technology can distinguish patients with large-vessel occlusion strokes and large hemorrhagic strokes versus less-urgent strokes. The company hopes emergency responders will use its unique diagnostic visor to shorten the time it takes for patients suffering major strokes to get to a hospital that has the facilities to treat the stroke effectively.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.